Clinical Trial Update: Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating temsirolimus in combination with sorafenib for advanced hepatocellular carcinoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Philipps University Marburg | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN